Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for alleged violations of securities laws, claiming the company made false and misleading statements regarding its competitive position and sales in the electrophysiology market [1][4]. Summary by Sections Class Action Details - Investors who purchased Integer's securities between July 25, 2024, and October 22, 2025, are encouraged to contact the Schall Law Firm before February 9, 2026, to participate in the lawsuit [2]. Allegations Against the Company - The complaint alleges that Integer exaggerated its competitive positioning in the electrophysiology market and falsely claimed that EP devices would be a long-term growth driver within the cardio and vascular segment [4]. - The company reportedly experienced a decline in sales of various EP devices, leading to misleading public statements throughout the class period [4]. Legal Representation - The Schall Law Firm specializes in securities class action lawsuits and offers free consultations to discuss rights related to the case [3][5].

Core Viewpoint - STAAR Surgical Company has received a favorable recommendation from Institutional Shareholder Services regarding its merger with Alcon, urging stockholders to vote in favor of the amended merger agreement [1] Company Summary - STAAR Surgical Company is recognized as the global leader in phakic IOLs, specifically with its EVO family of Implantable Collamer® Lenses designed for vision correction [1] Industry Context - The recommendation from ISS reflects a positive outlook on the merger, which may influence shareholder sentiment and the overall market perception of STAAR's strategic direction [1]

Core Insights - Vivos Therapeutics, Inc. is a medical device and healthcare services company focused on diagnosing and treating sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [1][3] - The company will participate in a fireside chat to discuss its strategic business model pivot, operational execution, market opportunities, competitive environment, and growth strategies [2] Company Overview - Vivos Therapeutics, founded in 2016 and based in Littleton, Colorado, specializes in innovative diagnostic and treatment methods for breathing and sleep issues related to dentofacial abnormalities [3][5] - The company's devices are FDA-cleared for treating all severity levels of OSA in adults and moderate-to-severe OSA in children aged 6 to 17 [3] - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for severe OSA treatment in adults and the first for moderate to severe OSA in children [3] Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [4] - Traditional OSA treatments, such as CPAP, often fail to address the root causes of the disorder, indicating a significant market opportunity for innovative solutions [4] Treatment Approach - Vivos employs a proprietary treatment method known as The Vivos Method, which is nonsurgical, noninvasive, and nonpharmaceutical, aiming to provide effective solutions for OSA patients [6]

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Integer Holdings Corporation for possible securities fraud, potentially leading to a class action lawsuit on behalf of investors [1]. Group 1: Allegations of Misconduct - The filed complaint alleges that Integer materially overstated its competitive position in the electrophysiology manufacturing market [3]. - Despite claims of strong visibility into customer demand, Integer was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [3]. - Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about the Company's business and prospects [3].

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

New York, New York--(Newsfile Corp. - December 15, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/i ...

New York, New York--(Newsfile Corp. - December 15, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ ...

Summary of Trisalus Life Sciences Conference Call Company Overview - **Company**: Trisalus Life Sciences (NasdaqGM: TLSI) - **Focus**: Improving outcomes for patients with solid tumors in the liver, pancreas, and other areas through innovative delivery technologies [2][3] Core Technology and Market Opportunity - **Technology**: A catheter-based system that modulates pressure and flow to enhance drug delivery directly into tumors, minimizing off-target effects [3][4] - **Market Size**: The company operates in a market opportunity of approximately $500 million, with less than 10% market share currently [3][4] - **Growth Potential**: Rapid growth anticipated due to the versatility of the technology for various embolization applications [4] Innovations in Treatment - **Thyroid Artery Embolization**: A new approach developed by Dr. Juan Camacho, aimed at treating multinodular goiter as a minimally invasive alternative to surgery [10][12] - **Patient Outcomes**: The technology has shown a 50% reduction in post-procedure readmissions due to fewer complications [8][9] Multinodular Goiter Insights - **Prevalence**: Approximately 12% of the adult population worldwide has multinodular goiter, with a significant number undergoing thyroidectomies annually [17][18] - **Surgical Risks**: Many surgeries are performed by general surgeons, leading to disparities in outcomes compared to specialized surgeons [18][19] - **Symptoms and Complications**: Patients often experience significant morbidity, including hyperthyroidism and compressive symptoms [21][23] Treatment Paradigms - **Minimally Invasive Options**: Options include radioactive iodine, percutaneous ethanol injection, ablation, and thyroid artery embolization [25][31] - **Volume Considerations**: Larger nodules (>20 mL) are more effectively treated with thyroid artery embolization due to high recurrence rates with other methods [27][28] Clinical Evidence and Results - **Efficacy of Embolization**: Studies indicate that thyroid artery embolization can reduce thyroid volume by approximately 50% and improve hormone levels without causing hypothyroidism [36][37] - **Quality of Life Improvements**: Significant improvements in quality of life reported post-procedure, with a high euthyroid conversion rate in patients with hyperthyroidism [38][39] Future Directions - **Research and Guidelines**: Ongoing efforts to build robust clinical data and establish guidelines for patient selection and treatment protocols [54][56] - **Awareness and Training**: Emphasis on increasing awareness of the procedure among patients and healthcare providers, and ensuring proper training for practitioners [64][65] Conclusion - **Emerging Treatment**: Pressure-enabled thyroid artery embolization presents a promising alternative for patients with large goiters, particularly when surgery poses high risks [52][53] - **Multidisciplinary Approach**: Collaboration among various specialties is crucial for optimizing patient care and integrating this technology into standard practice [64][65]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious malfunctions and risks to patient safety [5] - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [5] - The firm claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Investors with a lot of money to spend have taken a bullish stance on Intuitive Surgical (NASDAQ:ISRG).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ISRG, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scann ...